Wolverine Trading, LLC Prothena Corp Public LTD CO Put Options Transaction History

Wolverine Trading, LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Feb 14, 2024	BUY	$32.31 - $52.32 $100,161 - $162,192	3,100 Added 72.09%	7,400 $268,000
Q3 2023 Nov 15, 2023	BUY	$47.3 - $70.6 $203,390 - $303,580	4,300 New	4,300 $207,000
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $427,720 - $1.03 Million	17,000 New	17,000 $1.01 Million
Q3 2021 Nov 12, 2021	BUY	$48.2 - $78.89 $154,240 - $252,448	3,200 New	3,200 $227,000
Q4 2020 Feb 12, 2021	SELL	$10.12 - $13.94 $125,487 - $172,856	-12,400 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$9.93 - $13.47 $27,804 - $37,716	-2,800 Reduced 18.42%	12,400 $123,000
Q2 2020 Aug 13, 2020	BUY	$9.56 - $12.51 $145,312 - $190,152	15,200 New	15,200 $156,000
Q1 2019 May 15, 2019	SELL	$10.32 - $14.49 $274,512 - $385,434	-26,600 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$8.73 - $13.74 $160,632 - $252,816	-18,400 Reduced 40.89%	26,600 $273,000
Q3 2018 Nov 14, 2018	BUY	$12.7 - $15.79 $374,650 - $465,805	29,500 Added 190.32%	45,000 $589,000
Q1 2018 May 15, 2018	BUY	$27.95 - $45.04 $433,225 - $698,120	15,500 New	15,500 $569,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $761M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.